Key result
Treatment with short-term low-molecular-weight heparin resulted in no thromboembolism at 18-month follow-up for a patient with heterozygous prothrombin G20210A mutation undergoing hip arthroscopy.
Why the study?
Hip arthroscopy carries a low risk of venous thromboembolism with no established thromboprophylaxis guidelines, posing management challenges for patients with high-risk thrombophilia such as prothrombin G20210A mutation.
Does short-term low-molecular-weight heparin prevent thromboembolism in a patient with heterozygous prothrombin G20210A mutation and prior VTE undergoing hip arthroscopy?
Case Report (n=1)
Does short-term low-molecular-weight heparin prevent thromboembolism in a patient with heterozygous prothrombin G20210A mutation and prior VTE undergoing hip arthroscopy?
Short-term low-molecular-weight heparin successfully prevented VTE in a high-risk patient with prothrombin G20210A mutation undergoing hip arthroscopy.
May support short-term LMWH in high-risk prothrombin G20210A carriers; leaves open confirmation in prospective trials.
CASE: We report on a patient with heterozygous prothrombin G20210A mutation (PTM) and a history of venous thromboembolism (VTE) after knee arthroscopy, who was undergoing hip arthroscopy. This common mutation has an overall prevalence of 2.0% and results in a 280% to 420% likelihood of thrombosis compared to patients without the mutation. CONCLUSIONS: Hip arthroscopy is associated with a low risk of VTE with currently no guidelines for thromboprophylaxis. Patients should be managed in relation to their risk factors utilizing a collaborative, individualized approach. Treatment with short-term low-molecular-weight heparin resulted in no thromboembolism at 18-month follow-up for this patient with PTM.
No takes yet. Share an insight, caveat, or question.
Parsa et al. (2019) conducted a case report in Heterozygous prothrombin G20210A mutation (PTM) and history of venous thromboembolism (n=1). Short-term low-molecular-weight heparin was evaluated on Thromboembolism. Treatment with short-term low-molecular-weight heparin resulted in no thromboembolism at 18-month follow-up for a patient with heterozygous prothrombin G20210A mutation undergoing hip arthroscopy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: